Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituxan and Doxil in Relapsed/Refractory B-Cell Lymphoma
NCT00244985Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 2005
- Primary completion
- Aug 2008
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, pegylated liposomal doxorubicin in B-cell non-Hodgkin lymphoma, sponsored by Roswell Park Comprehensive Cancer Center. Started Sep 2005; status: completed.
02
Drugs
rituximabpegylated liposomal doxorubicin
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00244985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244985.